PT  - JOURNAL ARTICLE
AU  - Hernandez, Rémi J.
AU  - El-Bouri, Wahbi K.
AU  - Madhusudhan, Savita
AU  - Zheng, Yalin
TI  - AI and the Eye – Integrating deep learning and <em>in silico</em> simulations to optimise diagnosis and treatment of wet macular degeneration
AID  - 10.1101/2024.02.13.23299445
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.13.23299445
4099  - http://medrxiv.org/content/early/2024/02/14/2024.02.13.23299445.short
4100  - http://medrxiv.org/content/early/2024/02/14/2024.02.13.23299445.full
AB  - This protocol describes the A-EYE Study and provides information about procedures for entering participants. Every care was taken in its drafting, but corrections or amendments may be necessary. These will be circulated to investigators in the Study. Problems relating to this Study should be referred, in the first instance, to the Chief Investigator.This study will adhere to the principles outlined in the UK Policy Framework for Health and Social Care Research (v3.2 10th October 2017). It will be conducted in compliance with the protocol, the UK General Data Protection Regulation and Data Protection Act 2018, and other regulatory requirements as appropriate.DESIGN Single centre non-interventional study of patients with age-related macular degeneration to develop computational models of disease prediction and treatment outcome involving analysis of macular OCTA scans.Primary ObjectiveTo develop a mathematical model (or in silico model) of blood flow and anti-VEGF transport in the retina that, in combination with AI-based analysis of macular OCTA scans and clinical data, can be used to predict treatment response in patients with neovascular age-related macular degeneration (nAMD).Secondary objectivesTo apply deep learning models in combination with in silico models of blood flow to OCTA analysis, to confirm diagnosis of nAMD and its clinical subtypes.To develop prognostic models to predict treatment outcome based on longitudinal patient follow-up.Using in silico simulations, to understand why certain patients do not respond optimally to anti-VEGF treatment.To define and simulate individualised anti-VEGF treatment for optimal response.OUTCOME MEASURES A validated in silico model of patient response to nAMD and anti-VEGF treatments tailored to individual patients using OCTA scans.Identify optimal intravitreal anti-VEGF therapy drug regime for individual patients using in silico modelsImprove on the classification and characterisation of neovascular AMD into its subtypesPredict risk factors for poor treatment outcomes such as retinal vascular topologyPOPULATION ELIGIBILITY All patients aged 55 years or more, with a new diagnosis of nAMD in at least one eye, attending the Macular Clinic at Royal Liverpool University Hospital, who have had a macular OCTA scan at baseline i.e. at the time of diagnosis.DURATION 48 monthsClinical Queries Clinical queries should be directed to Dr Savita Madhusudhan who will re-direct the query to the appropriate person if necessary.Sponsor The University of Liverpool is the research Sponsor for this Study. For further information regarding the sponsorship conditions, please contact:Alex AstorHead of Research Support – Health and Life SciencesUniversity of LiverpoolResearch Support Office2nd Floor Block D Waterhouse Building3 Brownlow StreetLiverpool L69 3GLsponsor{at}liv.ac.uk mailto:Astor{at}liv.ac.ukFunder EPSRC DTP in AI and Future Digital Health is funding the studentship associated with this study. Mr Remi Hernandez is the PhD candidate holding the studentship and Dr El-Bouri, Prof Zheng, and Dr Madhusudhan are his supervisors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by 'Bayer plc' through a grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee "London - London Bridge Research Ethics Committee" gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesN/AHRAHealth Research AuthorityRECResearch Ethics CommitteeAIArtificial intelligenceCNNConvolutional Neural NetworkOCTOptical coherence tomographyOCTAOptical coherence tomography angiographynAMDNeovascular age-related macular degenerationMNVMacular neovascularisationanti-VEGFanti-Vascular Endothelial Growth FactorFAFluorescein AngiographyICGAIndocyanine Green Angiography